PCK2

Across TCGA pan-cancer cohorts, PCK2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PCK2 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PCK2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PCK2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where PCK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.886	.002	55	view →
PDAC	DFS	Tertile	All	0.586	0.353	.017	21	view →
GBM	OS	Median	All	0.422	0.651	.003	10	view →
LUAD	OS	Median	III,IV	0.218	0.674	.007	8	view →
COAD	DFS	Quartile	II,III,IV	1.000	0.900	.048	6	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	2	view →
LSCC	OS	Tertile	All	0.928	0.813	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PCK2–CCRCC (OS)

Open the CCRCC breakdown →